Search Results
Jul 06, 2026, 08:00 ET Matica Bio and VaxDome Partner to Develop Antigen-Agnostic Antiviral-Vaccine Hybrids with Influenza as One of the Disease Models
July 6, 2026 /PRNewswire/ -- Matica Biotechnology, Inc. ("Matica Bio"), a viral vector contract development and manufacturing organization (CDMO), is partnering with Texas-based biotech VaxDome Inc. to bring its novel antigen-agnostic antiviral-vaccine hybrid candidates into clinical trials. Under
More news about: Matica Biotechnology, Inc.
Jul 01, 2026, 20:05 ET Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases
collaboration, we are immediately enabling our customers to translate promising CNS assets into viable therapeutics. By combining this with flexible CDMO services, we allow partners to engage with us at any stage of their journey – from technology licensing to fully integrated development and commercial
More news about: Nona Biosciences
Jul 01, 2026, 10:46 ET Global Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsight
market.Asia-PacificThe Asia-Pacific region is becoming a key engine of growth for the oncology-based in-vivo CRO (CDMO) market, supported by a combination of cost competitiveness, a rapidly expanding biopharmaceutical sector, and continuous advancements in research capabilities. Major
More news about: DelveInsight Business Research, LLP
Jul 01, 2026, 08:52 ET ProBio's AAV Manufacturing Excellence Powers UC Irvine and GlyTR Therapeutics First‑in‑Class pan-cancer CAR‑T Program
Therapeutics, ProBio successfully delivered AAV scale‑up materials to enable in vivo IND-enabling studies. The program leverages ProBio's integrated CDMO capabilities including plasmid DNA development, GMP manufacturing, and scalable CMC expertise to de‑risk early development and accelerate the path toward
More news about: ProBio Inc.
Jul 01, 2026, 07:00 ET Avista Healthcare Partners Acquires Sanotact Group GmbH
platform with a differentiated position across both contract manufacturing and branded products. At closing, the business brings together a leading CDMO offering with broad formulation and dosage capabilities, alongside an established branded presence in the German market and a growing international
More news about: Avista Healthcare Partners
Jun 30, 2026, 10:17 ET Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics
other modified oligonucleotides, including 2'-OMe, 2'-F, phosphorothioate (PS), and GalNAc conjugation technologies.Small Nucleic Acid Drug CDMO Platform: Services covering hit screening, lead optimization, process development, analytical testing, and IND-enabling studies.Analytical
More news about: Tsingke Biotech
Jun 30, 2026, 10:17 ET Tsingke Biotech Hosts Shanghai Salon on Oligonucleotide Drugs, Spotlighting Next-Gen RNA Therapeutics
other modified oligonucleotides, including 2'-OMe, 2'-F, phosphorothioate (PS), and GalNAc conjugation technologies.Small Nucleic Acid Drug CDMO Platform: Services covering hit screening, lead optimization, process development, analytical testing, and IND-enabling studies.Analytical
More news about: Tsingke Biotech
Jun 30, 2026, 09:26 ET Salt Medical obtient la certification ISO 13485, renforçant ainsi sa position de partenaire sur l'ensemble du cycle de vie pour les entreprises du secteur des dispositifs médicaux
dispositifs médicaux évoluant dans des environnements fortement réglementés.En tant qu'organisation de développement et de fabrication sous contrat (CDMO) spécialisée dans les dispositifs médicaux couvrant l'ensemble du cycle de vie, Salt Medical accompagne ses clients de la conception à la commercialisation,
More news about: Salt Medical
Jun 30, 2026, 07:00 ET Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
June 30, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), published its annual environmental, social, and governance (ESG) report, highlighting continued progress in sustainable operations, responsible business
More news about: Samsung Biologics
Jun 30, 2026, 04:00 ET Salt Medical Achieves ISO 13485 Certification, Reinforcing Its Position as a Full-Lifecycle Partner for Medical Device Companies
strengthening the company's ability to support medical device innovators operating in highly regulated environments.As a full-lifecycle Medical Device CDMO, Salt Medical supports customers from concept through to commercialisation, providing expertise across design and development, manufacturing and commercial
More news about: Salt Medical
Jun 30, 2026, 04:00 ET Salt Medical Achieves ISO 13485 Certification, Reinforcing Its Position as a Full-Lifecycle Partner for Medical Device Companies
strengthening the company's ability to support medical device innovators operating in highly regulated environments.As a full-lifecycle Medical Device CDMO, Salt Medical supports customers from concept through to commercialisation, providing expertise across design and development, manufacturing and commercial
More news about: Salt Medical
Jun 30, 2026, 04:00 ET Salt Medical erhält die Zertifizierung nach ISO 13485 und festigt damit seine Position als Full-Lifecycle-Partner für Medizinproduktehersteller
Fähigkeit des Unternehmens weiter stärkt, Innovatoren im Bereich Medizinprodukte zu unterstützen, die in stark regulierten Umgebungen tätig sind.Als CDMO für Medizinprodukte, das den gesamten Lebenszyklus abdeckt, begleitet Salt Medical seine Kunden vom Konzept bis zur Markteinführung und stellt sein
More news about: Salt Medical
Jun 30, 2026, 01:49 ET WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
please visit: www.wuxibiologics.com. *The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)*The winner of the "2026 Best Contract Development & Manufacturing Organization
More news about: WuXi Biologics
Jun 30, 2026, 01:36 ET EirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026
Chain Restructuring Elevates the Strategic Role of CDMO PartnersBeyond biosimilars, CDMO services represent a second core pillar of EirGenix's
More news about: EirGenix
Jun 29, 2026, 12:00 ET Frontage Laboratories Is Pleased to Welcome Dr. Chandra Prakash, Ph.D., as Senior Advisor, Clinical Services
EXTON, Pa., June 29, 2026 /PRNewswire/ -- Frontage Laboratories, Inc. ("Frontage"), a leading global CRO/CDMO, is pleased to welcome Dr. Chandra Prakash, Ph.D., as Senior Advisor, Clinical Services. Dr. Prakash is internationally recognized for his scientific
More news about: Frontage Laboratories, Inc.
Jun 25, 2026, 07:45 ET AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
including oncology supportive care. Valion Bio's wholly owned subsidiary, Velocity Bioworks, a contract development and manufacturing organization (CDMO), currently provides biomanufacturing services to Valion, and is working towards providing services to third-party biotech companies in the future. For
More news about: Valion Bio, Inc.
Jun 24, 2026, 08:00 ET Phosphorex to Host a Virtual Panel Discussion Exploring Targeted Lipid Nanoparticle Development for Extrahepatic Delivery
xtalks.com/webinars/streamline-targeted-lnp-development-to-improve-preclinical-translation/About Phosphorex Founded in 2005 and headquartered in Hopkinton, Massachusetts, Phosphorex is a CDMO specializing in particulate drug delivery systems. The company's integrated capabilities span lipid nanoparticle (LNP), polymeric nanoparticle (PNP),
More news about: Phosphorex LLC
Jun 24, 2026, 02:39 ET WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
please visit: www.wuxibiologics.com. *The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)*The winner of the "2026 Best Contract Development & Manufacturing Organization
More news about: WuXi Biologics
Jun 23, 2026, 10:00 ET UPSHER-SMITH EXPANDS KYMBEE™ (DEFLAZACORT) FAMILY OF PRODUCTS WITH LAUNCH OF ORAL SUSPENSION FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet
More news about: Upsher-Smith Laboratories, LLC
Jun 23, 2026, 09:30 ET Orphan Therapeutics Accelerator Expands its Network to Extend Development and Access Pathways for Ultra-Rare Disease Therapies
SK pharmteco is a global contract development and manufacturing organization (CDMO) providing end-to-end services across process development, clinical and commercial manufacturing, and analytical testing. The company supports a range
More news about: Orphan Therapeutics Accelerator (OTXL)
Jun 23, 2026, 09:11 ET Wheeler Bio Launches New Website Reflecting Expansion of Capabilities, Clients Served, and a Commitment to High-Science, High-Touch Biologics Manufacturing
Wheeler Bio unveils its redesigned website, highlighting expanded capabilities as a fully integrated CDMO, now supporting biologics from gene to cGMP manufacturing with its signature ModularCMC™ platform.OKLAHOMA CITY, June
More news about: Wheeler Bio, Inc.
Jun 23, 2026, 06:44 ET Piramal Pharma Solutions evidenzia solidi risultati in oltre 200 audit dei clienti
come partner CDMO globale affidabile.MUMBAI, India, 23 giugno 2026 /PRNewswire/ -- Piramal Pharma Solutions ("PPS"), una delle principali Contract Development and Manufacturing Organization (CDMO) a livello globale
More news about: Piramal Pharma Solutions
Jun 22, 2026, 20:00 ET CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation
strengthening domestic partnerships, and cross-border collaborations forming in every direction. Underpinned by Korea's leading pharma manufacturing, advanced CDMO infrastructure, and fast-growing nutraceutical market, the show serves as a strategic platform for business across Asia and beyond.Major government
More news about: Informa Markets Korea
Jun 22, 2026, 20:00 ET CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation
strengthening domestic partnerships, and cross-border collaborations forming in every direction. Underpinned by Korea's leading pharma manufacturing, advanced CDMO infrastructure, and fast-growing nutraceutical market, the show serves as a strategic platform for business across Asia and beyond.Major government
More news about: Informa Markets Korea
Jun 22, 2026, 13:46 ET Alcami Expands Quality, Packaging, and Storage Capabilities at Tennessee Facility
June 22, 2026 /PRNewswire/ -- Alcami Corporation ("Alcami"), the leading contract development and manufacturing organization (CDMO), today announced a series of strategic and operational investments at its Tennessee facility, which was recently added to the company's network through
More news about: Alcami